Congresses

Title Yearsort descending
Resistance to selamectin in Mycobacterium smegmatis is associated with changes in the mycobacterial envelope 2020
Expert Campus | Focus on tuberculosis 2020
Fighting Mycobacterium abscessus infection in Cystic Fibrosis patients 2020
Enzymatic inhibition of Mycobacterium tuberculosis DprE1 protein by the anti-parasitic selamectin lacks translation into phenotypic activity 2021
Approaches to elucidate the mode of action of a novel chemical series active against mycobacteria 2021
Clinical trial design optimisation and dose rationale for the treatment of Buruli ulcer antibiotic combination therapy 2021
Repurposing beta-lactams for Buruli ulcer therapy, from the bench to the clinic. 2021
Strategies to elucidate the mode of action of the avermectins against mycobacteria 2021
Beta-lactams against Mycobacterium kansasii 2021
Novel in vitro synergistic combinations in the treatment of non-tuberculous mycobacteria 2021
In vitro synergy screens of FDA-approved drugs combined with last-line antibiotics reveal new bactericidal combinations against Klebsiella pneumoniae 2022
Hollow fiber system for tuberculosis setting up at university of Zaragoza 2022
Shortening Buruli ulcer treatment: the BLMs4BU clinical trial 2022
In vitro killing dynamics of the diarylquinolone TBAJ-587 and its main metabolites against Mycobacterium tuberculosis 2022
Shortening Buruli ulcer treatment: WHO recommended <i>vs.</i> a novel betalactam containing therapy - Phase II and Phase III studies in West Africa (the BLMs4BU clinical trial) 2022
OPTIKA, A New High Content Drug Combination Kill Kinetic Assay 2022
Hollow fiber system for TB: optimization studies with Moxifloxacin 2022
OPTIKA – a new high content drug combination dynamic assay / Hollow-fibre models 2022
A new weapon against Mycobacterium abscessus 2022
In vitro time-kill assays of amoxicillin/clavulanate in combination with rifampicin/clarithromycin against Mycobacterium ulcerans 2022

Pages